Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04092283
Title Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Paclitaxel

Cisplatin + Etoposide

Cisplatin + Durvalumab + Etoposide

Carboplatin + Durvalumab + Paclitaxel

Durvalumab

Cisplatin + Durvalumab + Pemetrexed Disodium

Cisplatin + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.